Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
24.37
+0.08 (+0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,245,159
Open
24.41
Bid (Size)
24.36 (52)
Ask (Size)
24.37 (5)
Prev. Close
24.29
Today's Range
24.24 - 24.71
52wk Range
22.01 - 32.88
Shares Outstanding
166,121,384
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
June 19, 2024
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
The Analyst Landscape: 7 Takes On Alkermes
June 17, 2024
Via
Benzinga
Performance
YTD
-14.85%
-14.85%
1 Month
+0.74%
+0.74%
3 Month
-6.02%
-6.02%
6 Month
-17.67%
-17.67%
1 Year
-17.78%
-17.78%
More News
Read More
In a market where value is scarce, NASDAQ:ALKS offers a refreshing opportunity with its solid fundamentals.
May 29, 2024
Via
Chartmill
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
May 25, 2024
Via
InvestorPlace
6 Analysts Assess Alkermes: What You Need To Know
May 23, 2024
Via
Benzinga
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
May 08, 2024
Via
Chartmill
7 Analysts Assess Alkermes: What You Need To Know
May 02, 2024
Via
Benzinga
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
May 02, 2024
Via
Chartmill
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
April 10, 2024
Via
Chartmill
Breaking Down Alkermes: 5 Analysts Share Their Views
April 09, 2024
Via
Benzinga
ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024
May 01, 2024
Via
InvestorPlace
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
April 17, 2024
Via
Chartmill
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
April 09, 2024
Via
Benzinga
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
March 27, 2024
Via
Chartmill
Is NASDAQ:ALKS suited for growth investing?
March 20, 2024
Via
Chartmill
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
March 19, 2024
Via
Benzinga
Exploring NASDAQ:ALKS's growth characteristics.
February 28, 2024
Via
Chartmill
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
March 11, 2024
Via
Benzinga
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
Via
Investor's Business Daily
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
March 05, 2024
Via
Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Via
Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
February 23, 2024
Via
Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
February 21, 2024
Via
InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
February 15, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.